Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside

@article{Shabbir2010LestaurtinibAM,
  title={Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside},
  author={Munira Shabbir and Robert K. Stuart},
  journal={Expert Opinion on Investigational Drugs},
  year={2010},
  volume={19},
  pages={427 - 436}
}
Importance of the field: Internal tandem duplication of the fms-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) is a common recurring mutation in acute myeloid leukemia (AML) with normal karyotype, and the presence of FLT3-ITD confers a poor prognosis on this large subgroup of AML patients. Since the discovery of lestaurtinib as a potent FLT3 inhibitor, in 1985, there has been considerable interest in the development of this agent (CEP-701, Cephalon, Frazer, PA, USA) for treatment of this… 
FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.
TLDR
This review focuses on the role of FLT3 mutations in AML, pharmacological features ofFLT3 inhibitors, known mechanisms of drug resistance and accumulated evidence for the use of FLt3 inhibitors in different clinical settings.
Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I
TLDR
While many novel Trk inhibitors remain the original progeny of Trk-specific development programs, kinase inhibitors initially developed for other kinases have also been successfully repositioned for Trk.
New Kinase Inhibitors for the Treatment of Chronic Hematological Neoplasms-Editorial
TLDR
Despite very good results of current CML treatment, there is still room for improvement in the treatment of patients with CML, and several drugs with an inhibitory action towards the Aurora kinase family have been developed.
Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
TLDR
These findings provide, for the first time, a molecular rationale for testing JAK2 inhibitors, specifically Lestaurtinib, in HL patients and help clarify the role of JAK/STAT constitutive activation in HL.
Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II
TLDR
The observed potential of Trk inhibitors to cause adverse CNS side effects however suggests the need for a more rigorous consideration of BBB permeation capabilities during drug development.
JAK2 inhibitors in the treatment of myeloproliferative neoplasms
TLDR
Understanding the intricacies of JAK-STAT pathway activation, including growth factor/cytokine-driven signaling, will open new avenues for therapeutic intervention at known and novel molecular vulnerabilities of MPNs.
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial
TLDR
A single-centre, randomised, placebo-controlled trial design that leverages the multiplicity of tumours seen in an inherited skin tumour syndrome that may inform the design of other studies in similar genetic diseases is presented.
Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013
TLDR
This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets, and considers recent progress in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation.
Recent advances in FLT3 inhibitors for acute myeloid leukemia.
TLDR
This review outlines the evolution of AML-targeting FLT3 inhibitors by focusing on their chemotypes, selectivity and activity overFLT3 wild-type and FLT2 mutations as well as new techniques related to FLT 3.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
TLDR
The proapoptotic IAP inhibitor, LBW242, was shown in proliferation studies done in vitro to enhance the killing of PKC412-sensitive and PKC 412-resistant cell lines expressing mutant FLT3 when combined with either PKC512 or standard cytotoxic agents (doxorubicin and Ara-c).
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
Internal tandem duplication mutations of FLT3 (FLT3/ITD mutations) are common in acute myeloid leukemia (AML) and confer a poor prognosis. This would suggest that FLT3 is an ideal therapeutic target,
Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.
TLDR
KC412 demonstrates a high rate of MRs and PRs in this initial cohort of advanced SM pts, supporting further accrual in this Simon two-stage trial.
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
TLDR
Investigation of the inhibitory effects of AG1296 on FLT3/ITDs isolated from AML patients in the IL-3-dependent cell line, Ba/F3, as well as in primary leukemia samples fromAML patients, suggest that inhibiting the activity ofFLT3 may have a therapeutic value in some leukemias expressing FLT 3/ ITDs.
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
TLDR
These findings support the continued clinical assessment of FLT3 inhibitors in combination with cytotoxic chemotherapy and suggest entry to future clinical trials should includeFLT3 wild-type patients and should remain unrestricted by FLT2 expression level.
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
TLDR
The data provide a rationale for combining tandutinib with induction chemotherapy in intensified as well as in dose reduction protocols for FLT3 ITD-positive AML and demonstrate, that addition of tandUTinib may allow dose reduction of chemotherapy without loss of overall antileukemic activity – but with a resultant decrease of potential side effects.
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
TLDR
The combination of PKC412 together with chemotherapeutic drugs is more effective in FLT3/ITD positive AML cells and more synergistic and less antagonistic effects compared to combinations with ara-C and daunorubicin, in both patient material and cell lines.
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
TLDR
A novel class of FLT3 inhibitors is presented that displays high selectivity and potency towardFLT3 as a molecular target, and which could potentially be used to override drug resistance in AML.
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
TLDR
It is found that lestaurtinib inhibits the growth of HEL92.1.7 cells, which are dependent on mutant JAK2 activity for growth in vitro and in xenograft models, and therefore holds promise as a therapeutic agent for patients with these disorders.
...
1
2
3
4
5
...